Does EDAP TMS S.A. (EDAP) Have Any Gas After Forming This Multiple Bottom Pattern?

June 20, 2018 - By Michael Collier


The stock of EDAP TMS S.A. (EDAP) shows a multiple bottoms pattern with $3.07 target or 4.00 % below today’s $3.20 share price. The 5 months chart pattern indicates high risk for the $92.79M company. It was reported on Jun, 20 by If the $3.07 price target is reached, the company will be worth $3.71 million less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock decreased 0.31% or $0.01 during the last trading session, reaching $3.2. About 114,432 shares traded. EDAP TMS S.A. (NASDAQ:EDAP) has declined 14.64% since June 20, 2017 and is downtrending. It has underperformed by 27.21% the S&P500.

Analysts await EDAP TMS S.A. (NASDAQ:EDAP) to report earnings on August, 22. They expect $-0.02 EPS, up 60.00 % or $0.03 from last year’s $-0.05 per share. After $0.03 actual EPS reported by EDAP TMS S.A. for the previous quarter, Wall Street now forecasts -166.67 % negative EPS growth.

More notable recent EDAP TMS S.A. (NASDAQ:EDAP) news were published by: which released: “Pre-Open Movers 06/08: (EDAP) (ZUMZ) (SFIX) Higher; (CXO) (MVIS) (LITE) Lower (more…)” on June 08, 2018, also with their article: “Mid-Day Market Update: EDAP Rises Following FDA Clearance Of Focal One Device; MicroVision Shares Plunge” published on June 08, 2018, published: “Monster Stock Climbs to Top of S&P; Apple Supplier Sinks” on June 08, 2018. More interesting news about EDAP TMS S.A. (NASDAQ:EDAP) were released by: and their article: “Benzinga’s Daily Biotech Pulse: EDAP Device Gets FDA Nod, Ampliphi Presents Positive Data, Agile To Cut Jobs” published on June 10, 2018 as well as‘s news article titled: “EDAP TMS SA : EDAP Announces FDA Clearance for Focal One®” with publication date: June 07, 2018.

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company has market cap of $92.79 million. The firm operates in two divisions: High Intensity Focused Ultrasound , and Urology Devices and Services (UDS). It currently has negative earnings. The HIFU division develops, makes, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: